News
KLRS
3.245
+1.41%
0.045
Weekly Report: what happened at KLRS last week (0914-0918)?
Weekly Report · 16h ago
Weekly Report: what happened at KLRS last week (0907-0911)?
Weekly Report · 09/14 10:25
Weekly Report: what happened at KLRS last week (0831-0904)?
Weekly Report · 09/07 10:18
Weekly Report: what happened at KLRS last week (0824-0828)?
Weekly Report · 08/31 10:26
Weekly Report: what happened at KLRS last week (0817-0821)?
Weekly Report · 08/24 10:26
Weekly Report: what happened at KLRS last week (0810-0814)?
Weekly Report · 08/17 10:28
Analysts Offer Insights on Healthcare Companies: Airsculpt Technologies (AIRS), Biohaven Ltd. (BHVN) and Kalaris Therapeutics (KLRS)
TipRanks · 08/12 11:50
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Kalaris Therapeutics (KLRS)
TipRanks · 08/11 21:10
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Kalaris Therapeutics (KLRS)
TipRanks · 08/11 19:20
Kalaris Therapeutics GAAP EPS of -$0.48 in-line
Seeking Alpha · 08/11 12:09
Weekly Report: what happened at KLRS last week (0803-0807)?
Weekly Report · 08/10 10:22
Weekly Report: what happened at KLRS last week (0727-0731)?
Weekly Report · 08/03 10:22
Weekly Report: what happened at KLRS last week (0720-0724)?
Weekly Report · 07/27 10:26
Kalaris Therapeutics Strengthens Financial Leadership With New CFO
TipRanks · 07/20 12:29
Kalaris Therapeutics Appoints Liisa Bayko CFO
Benzinga · 07/20 12:03
*Kalaris Therapeutics Says Bayko Is Strategic Finance Leader With Over 20 Yrs of Experience in Biotechnology Space >KLRS
Dow Jones · 07/20 12:02
*Kalaris Therapeutics Appoints Liisa Bayko as Chief Fincl Officer >KLRS
Dow Jones · 07/20 12:01
Press Release: Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Dow Jones · 07/20 12:00
Judah Frommer Maintains Buy on KLRS as TH103 Data Strengthen Risk‑Reward, Keeps Price Target Unchanged at $14
TipRanks · 07/20 11:25
Weekly Report: what happened at KLRS last week (0713-0717)?
Weekly Report · 07/20 10:22
More
Webull provides a variety of real-time KLRS stock news. You can receive the latest news about Kalaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).